Targeted therapy of RET fusion-positive non-small cell lung cancer

Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with considerable efficacy. The RET proto-oncogene is...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Zixiong, Qiu, Binxu, Li, Lin, Yang, Bo, Li, Guanghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793070/
https://www.ncbi.nlm.nih.gov/pubmed/36582799
http://dx.doi.org/10.3389/fonc.2022.1033484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793070/
https://www.ncbi.nlm.nih.gov/pubmed/36582799
http://dx.doi.org/10.3389/fonc.2022.1033484

Ejemplares similares